On Jan. 4, clinicians across New York State booted up their computers and logged into a virtual classroom, each ready to learn how to improve care for their HIV patients.
Within the next few years, several pipeline hepatitis C drugs are expected to be approved in the U.S., ensuring that even the most difficult-to-treat patients can be cured -- but what challenges remain?
Despite the diversity of new direct-acting antivirals (DAAs), a tiny number of patients are still left behind. Nancy Reau, M.D., presented a summary of soon-to-be-approved drugs that should work for these tough-to-treat patients.
While restrictions for obtaining hepatitis C drugs through Medicaid programs vary state by state, restrictions eased somewhat across the country from 2014 to 2016, according to data presented at the Liver Meeting 2016.
A health program called Project ECHO successfully used telecommunication technology to coach local care providers on how to treat hepatitis C in New Mexico. Now its founder wants to expand the program to the rest of the world and all primary care....
A staggering 38% of new HIV infections among low-income women in the U.S. may be due to anal intercourse, which is poorly understood in women, according to a study presented at HIVR4P 2016.
While a true cure remains elusive for both diseases, HIV researchers are looking at new advances in immuno-oncology for clues on how to achieve durable HIV remission.
In this interview, Carl Dieffenbach, Ph.D., director of the Division of AIDS, National Institute of Allergy and Infection Diseases (NIAID), shares his thoughts on the challenges and opportunities ahead on the road toward an HIV cure.